Astellas Pharma and Pfizer have announced unprecedented results from the pivotal Phase 3 EV-303 clinical trial (KEYNOTE-905), with the combination of PADCEV (enfortumab vedotin) and MSD's KEYTRUDA (pembrolizumab) delivering significant survival benefits for cisplatin-ineligible patients with muscle-invasive bladder cancer. …
New combination therapy sets landmark survival benchmark in bladder cancer treatment
October 19, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
The 'Dispatched' Week in Review' Podcast - 7 November
November 7, 2025 - - Podcast -
Donald Trump announces 'MFN' deals with Lilly and Novo Nordisk and end to 'global freeloading'
November 7, 2025 - - Latest News -
Sanofi employees contribute over 400 volunteer hours to community and environmental causes
November 6, 2025 - - Latest News -
Neuren posts record royalties as DAYBUE sales surpass US$100 million in third quarter
November 6, 2025 - - Australian Biotech -
US Ambassador warns UK risks losing pharma investment unless it pays more for medicines
November 6, 2025 - - Latest News -
Pfizer to continue legal fight as court rejects bid to block Novo Nordisk’s Metsera takeover bid
November 6, 2025 - - Latest News -
What next for PBS rebate system amid constitutional breaches, disputed claims, and global pressure?
November 6, 2025 - - Latest News